INCPF (InnoCare Pharma) 3-Month Share Buyback Ratio: 0.00% (As of Dec. 2025 )

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

INCPF InnoCare Pharma Ltd INCPF
83 GF Score
Price $1.55
GF Value $2.32
! 7 Warning Signs
View Full Analysis

What is InnoCare Pharma 3-Month Share Buyback Ratio?

InnoCare Pharma INCPF 83 3-Month Share Buyback Ratio is 0.00 as of Dec. 2025. GuruFocus rates INCPF with a GF Score™ of 83/100 and a GF Value™ of $2.32. The stock has 7 warning signs investors should review.

3-Month Share Buyback Ratio only apply to companies whose reporting frequency is 3 months.

INCPF
83GF Score
InnoCare Pharma Ltd INCPF
3-Month Share Buyback Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a 3-Month Share Buyback Ratio of 0.00 mean?
InnoCare Pharma (INCPF) has a 3-Month Share Buyback Ratio of 0.00 as of Dec. 2025. The 3-Month Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past three months, calculated as the percentage change in shares outstanding from the previous quarter to the current quarter. View historical data for InnoCare Pharma and its competitors.
Is InnoCare Pharma's 3-Month Share Buyback Ratio too high?
InnoCare Pharma's current 3-Month Share Buyback Ratio is 0.00. Overall, InnoCare Pharma has a GF Score™ of 83/100, reflecting its overall financial health beyond just this single metric.
How does InnoCare Pharma's 3-Month Share Buyback Ratio compare to VRTX and REGN?
InnoCare Pharma's 3-Month Share Buyback Ratio of 0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Month Share Buyback Ratio for a Biotechnology company?
A good 3-Month Share Buyback Ratio depends on the Biotechnology industry context. However, 3-Month Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Month Share Buyback Ratio mean?
A high 3-Month Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 3-Month Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past three months, calculated as the percentage change in shares outstanding from the previous quarter to the current quarter. View historical data for InnoCare Pharma and its competitors. InnoCare Pharma's current 3-Month Share Buyback Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InnoCare Pharma stock overvalued right now?
InnoCare Pharma (INCPF) has a current 3-Month Share Buyback Ratio of 0.00. The stock's GF Value™ is $2.32, compared to a current price of $1.55 — trading 33.2% below its estimated fair value. The current 3-Month Share Buyback Ratio is 0.00. InnoCare Pharma's overall GF Score™ is 83/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Month Share Buyback Ratio calculated?
3-Month Share Buyback Ratio is calculated from a company's financial statements. For InnoCare Pharma (INCPF), the current 3-Month Share Buyback Ratio is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is InnoCare Pharma (INCPF) Overvalued in 2026?

Based on GuruFocus' analysis, InnoCare Pharma stock appears to be undervalued. The current stock price of $1.55 is trading 33.2% below its estimated GF Value™ of $2.32.

Key valuation signals for INCPF:

  • 3-Month Share Buyback Ratio: 0.00
  • GF Value™: $2.32 vs. price of $1.55 (33.2% below fair value)
  • GF Score™: 83/100 with 7 warning signs

No single metric tells the full story. See the INCPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

InnoCare Pharma Business Description

Address No. 8 Life Science Park Road, Building 8, Zhongguancun Life Science Park, Changping District, Beijing, CHN, 102206
InnoCare Pharma Ltd is a commercial-stage biopharmaceutical company. It discovers, develops, and commercializes drugs for the treatment of cancer and autoimmune diseases. The company's main product pipeline includes orelabrutinib, ibrutinib, zanubrutinib, tafasitamab, ICP-490, ICP-B02, ICP-248, ICP-192, ICP-723, and ICP-189, among others. Its products are mainly used to treat hematological tumors, solid tumors, and autoimmune diseases. The company is also developing products for the treatment of autoimmune diseases caused by abnormal B-cell or T-cell function.
83GF Score

Get the complete analysis for INCPF

3-Month Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.55
Price
$2.32
GF Value